Companies: 10,795·Total market cap: $144.5T
Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.

KTTANASDAQHealthcare● Active
$0.58
$-0.01(-1.61%)
Market Cap$4283703
P/E Ratio
52W High$2.06
52W Low$0.281
Overview

Pasithea Therapeutics Corp. (KTTA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KTTA · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.37ktta eps ttm · ktta earnings per shareEarnings history
PE Ratio (TTM)ktta pe ratio ttm · ktta price to earningsPE Ratio deep dive
Revenue (TTM)0.00ktta revenue ttm · ktta annual revenueFull revenue history
Dividend YieldNo Dividenddoes ktta pay dividends · ktta dividend yieldDividend history
Shares Outstanding7.0Mktta shares outstanding · ktta floatShares outstanding history
Next EarningsAug 13, 2026Est.ktta earnings date · ktta next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
pasithea therapeutics corp. revenue · ktta revenue 2025
FY 2025Net Income-$20.4M▼ 46.91% YoY
202320242025
pasithea therapeutics corp. net income · ktta profit 2025
FY 2025EPS$-2.91▲ +77.07% YoY
202320242025
ktta eps · pasithea therapeutics corp. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$19.7MEPS: $-2.37View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy2 analystsis ktta a buy · ktta analyst rating
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$3.00Low
$0.58Current
$3.00Avg Target421.20% upside
$3.00High
ktta price target · ktta 12 month forecast

Total: 2 · Buy rate: 100.0%

The KTTA analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $3.00, representing +421.20% upside from the current price of $0.58.

Stock Performance

Full History
1D+0.41%
1W-8.79%
1M-26.14%
3M-26.25%
YTD-54.47%
1Y-34.73%
5Y-99.17%

About Pasithea Therapeutics Corp.

CEOTiago Reis Marques
IPO DateSep 15, 2021
Employees4
CountryUS

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its …

what is pasithea therapeutics corp. · ktta stock overview · pasithea therapeutics corp. company profile · who is pasithea therapeutics corp. ceo · ktta NASDAQ · pasithea therapeutics corp. headquarters · pasithea therapeutics corp. business segments

About Stock Overview & Key Data

Pasithea Therapeutics Corp. (KTTA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 15, 2021. As of the latest trading session, KTTA stock price is $0.58, with a market capitalization of $4.3M. The stock has returned -34.73% over the past 12 months and -54.47% year-to-date.

According to 2 Wall Street analysts, the consensus rating for Pasithea Therapeutics Corp. stock is Buy, with an average 12-month price target of $3.00. In fiscal year 2025, Pasithea Therapeutics Corp. reported revenue of — and net income of -$20.4M. For detailed data — including Pasithea Therapeutics Corp. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Pasithea Therapeutics Corp. (KTTA) stock price is $0.58. The stock is traded on NASDAQ under the ticker symbol KTTA. The 52-week range is $0.28 – $2.06.

KTTA stock priceKTTA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice